Download programme pdf document

The organisation keeps the right to make changes to the programme at any time.

  • 08:00

    CxO breakfast meeting: for CEOs, CFOs, COOs and CBOs active in the life sciences sector

    Besides a nice and healthy breakfast new companies that started their business recently at the Leiden Bio Science Park will introduce themselves to the Life Sciences community.

    Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.

  • 08:00

    Investors forum part 1 - breakfast session -

    Hosted by Johnson & Johnson Innovation

    The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, med tech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.

  • 08:45


    Present your company, products, technology or service. Open from 08:45 till 19:30 hours.

  • 09:30

    Plenary opening programme

    Hosted by Leiden Bio Science Park

    • Welcome by chair

      Ida Haisma, Director Leiden Bio Science Park will guide us through the plenary programme.

    • Opening

      Opening by Carmen van Vilsteren, Chair Top Sector Life Sciences & Health

    • ´Novel manufacturing solutions for the rapid and cost-effective development of vaccines´

      by Alfred Luitjens, Global Technical Sales Director at Batavia Biosciences

      There is a constant demand for more affordable vaccines for global health (polio, measles, rubella), as well as new vaccines to protect against emerging virus outbreaks, such as Ebola, Lassa, Marburg, and coronavirus. To keep up with such demand, breakthrough technologies and global collaborations are required that allow flexible, cost-effective and rapid vaccine development. In this presentation, promising novel technologies, flexible manufacturing solutions and views on collaborations within the industry will be presented. These innovations have demonstrated to substantially lower the cost of goods and increase speed of manufacturing. Such innovations are deemed critical to stay ahead of the game and keep millions of people from dying from vaccine preventable diseases.

    • ´Large scale manufacturing of CAR-T personalized medicine at BMS´

      by Arjen Schippers, Senior Director and Program Head at Europe Cell Therapy Facility, Bristol Myers Squibb Leiden

      Presentation on the plans of BMS for the manufacturing of current and future CAR-T therapies in the EU.
      What are CAR-T therapies, what is the best way to produce them in the EU and what are some of the challenges that you can face during startup of a new site. What are the future manufacturing scenarios for BMS.

  • 10:50


    Time for networking and to visit the exhibition.

  • 11:30

    Parallel morning sessions

    The Nagoya protocol: its impact on research and development in life sciences

    Hosted by V.O.Patents & Trademarks

    Presentations by:
    Dr. Martin Brink, Policy Advisor at Centre for Genetic Resources, WUR
    Dr. Scarlett Sett, ABS Project Officer at Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures
    Dr. Noël van Peij, Principal Scientist DSM Food Specialties

    Advanced biopharmaceutical manufacturing

    Hosted by Pivot Park

    Presentations by:
    Dr. Nettie Buitelaar, Chief Business Officer at BiosanaPharma
    Mireille Sanders MSc, Chief Operations Officer at Pharming Group NV
    Alexander Willemse, CEO BioConnection

    Medical devices to respond to urgent needs

    Hosted by Quality by Design

    Presentations by
    ▪ Koen Beyers, Founder & Board Member at Voxdale
    ▪ David Nauwelaers, Director of Manufacturing miDiagnostics

  • 12:45


    Time for networking and to visit the exhibition.

    Q&A: Funding opportunities of Top Sector Life Sciences & Health @ Health~Holland Booth
    Are you in search of suitable ways to fund your innovative R&D solutions in the Life Sciences & Health (LSH) sector and are you part of a public-private partnership? Then come to the Q&A session of the Top Sector LSH and get informed. Three of our experts are happy to give you insight in the Top Sector’s funding opportunities and the terms and conditions.

  • 14:00

    Parallel afternoon programme

    Breakthrough technologies in life sciences

    Hosted by Leiden Bio Science Park 

    Presentations by.
    Jos Lunenberg MSc, MBA, Founder & CEO at ENPICOM BV
    Dr. Kirsten Schimmel, Ziekenhuisapotheker ¦ Sectiehoofd Bereidingen ¦ Associate Professor Drug Manufacturing at LUMC
    Frederico Muffatto, CEO Digi.Bio
    Jan Jaap Verhoef, Founder Imuno BV

    Human Microbiome: Novel therapeutic strategies and market developments

    Hosted by PwC

    Presentations by:
    Dr. Dries Budding, CEO inBiome
    Marco van Es, Founder Bac2nature
    Dr. Jonathan de Jonge, COO ARTPred

    Cell- and gene based therapeutics

    Hosted by Progress

    Presentations by
    Dr.Ir. Hugo Cueto Rojas, USP Lead Scientist uniQure
    Dr. Melissa van Pel, Head of Cell Therapy NecstGen
    Erik Agterhuis, Industry expert and former Director Supply Chain Cell Therapy at Kite Pharma

  • 15:15


    Time for networking and to visit the exhibition.

  • 16:00

    Plenary closing programme

    • Wrap up conference

    • Announcement winner Investors Forum

      The winner of the Investors Forum will be awarded a partnering ticket, national or international with a total value of EUR 2,500 and will present their pitch.

    • Mibiton Quality Certificate

      Already more than twenty-five years, dozens of young Life Sciences companies has already been able to accelerate their development, by using a Mibiton investment to purchase state-of-the art lab facilities or to produce first series of medical devices or agro-food production facilities. This year, the stem cell company Ncardia, with facilities at the Leiden Bio Science Park, was selected to receive the bi-annual “Mibiton Quality Certificate”. CEO Stefan Braam will briefly elaborate on the recent developments of his company, including the impact of both Mibiton investments.

    • ´TargED Biopharmaceuticals: from Idea to Company´

      by Kristof Vercruysse, CEO and Co-Founder TargED Biopharmaceuticals B.V.

      TargED Biopharmaceuticals, a private biotechnology company focused on developing improved treatments for thrombotic diseases, announced recently that it has raised Series A financing of EUR 39 million to accelerate development of its lead compound, Microlyse.

      Kristof will explain what are the necessary steps to go from idea towards clinical development! What are the do’s and don’ts while setting up your company for the next steps. Building a story that is comprehensible and reproducible, a strategy that even holds in difficult therapeutic areas.

    • Venture Challenge

      Hosted by Health~Holland

      The winners of the Venture Challenge Summer and Fall 2021 will be announced!

  • 17:30


    Drinks, bites, networking and visit the exhibition!


Stay up to date with the latest news!

Newsletter subscribe